Sign in

    Brian Jeep

    Senior Equity Research Analyst and Director specializing in pharmaceuticals at WallachBeth

    Brian Jeep is a Senior Equity Research Analyst and Director specializing in pharmaceuticals at WallachBeth Capital, where he conducts in-depth analysis of key companies in the healthcare and biotechnology sectors. He has provided extensive coverage of major pharmaceutical firms, leveraging a strong track record of delivering actionable investment insights, though specific public rankings and quantitative performance data are not disclosed. Brian began his analyst career at Wells Fargo, where he served as Vice President, before moving through various roles and ultimately joining WallachBeth Capital; he has also held leadership responsibilities at JeepCo. He holds advanced securities licenses and is registered with FINRA, reflecting a robust professional background in equity research and financial analysis.

    Brian Jeep's questions to TENAX THERAPEUTICS (TENX) leadership

    Brian Jeep's questions to TENAX THERAPEUTICS (TENX) leadership • Q3 2016

    Question

    Brian Jeep of WallachBeth asked about the projected Q4 cash burn, the company's business development strategy following the negative LeoPARDS trial results, plans for a potential capital raise in 2017, and the required size of the commercial sales force.

    Answer

    CFO Michael Jebsen explained that while recognized R&D expense will decrease, cash burn will remain as projected due to paying down previously accrued patient costs, resulting in a year-end cash balance of around $19 million. He also confirmed a likely capital raise in mid-to-late 2017 to finance commercial infrastructure, contingent on positive data. CEO John Kelley stated that business development activities continue unchanged and estimated a sales force of 60 to 70 representatives would be needed for launch.

    Ask Fintool Equity Research AI